NANJING, China, Aug. 13, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2013.

Highlights

Revenue from continuing operations for the second quarter of 2013 was RMB483.0 million (US$78.7 million), a decrease of 3.0% compared to RMB498.1 million for the same period in 2012. Revenue from continuing operations for the first six months of 2013 was RMB986.9 million (US$160.8 million), an increase of 2.9% from RMB959.1 million for the same period in 2012.

Gross margin from continuing operations for the second quarter of 2013 decreased to 83.1% compared to 84.5% for the same period in 2012. For the first six months of 2013, gross margin decreased to 81.5% compared to 83.8% for the same period in 2012.

Operating income from continuing operations was RMB10.7 million (US$1.7 million) for the second quarter of 2013, a decrease of 67.5% from RMB33.0 million for the same period in 2012. Operating income from continuing operations was RMB52.3 million (US$8.5 million) for the first six months of 2013, a decrease of 27.3% from RMB72.0 million for the same period in 2012.

Net income attributable to Simcere was RMB22.7 million (US$3.7 million) for the second quarter of 2013, a decrease of 15.7% from RMB27.0 million for the same period in 2012. Net income attributable to Simcere was RMB52.7 million (US$8.6 million) for the first six months of 2013, a decrease of 5.2% from RMB55.6 million for the same period in 2012.

Net income attributable to Simcere from continuing operations for the second quarter of 2013 was RMB8.2 million (US$1.3 million), a decrease of 57.6% from RMB19.4 million for the same period in 2012. Net income attributable to Simcere from continuing operations for the first six months of 2013 was RMB30.9 million (US$5.0 million), a decrease of 32.5% from RMB45.8 million for the same period in 2012.

On June 17, 2013, the Company entered into a share transfer agreement to sell its approximately 99.99% equity interest in Jilin Boda Pharmaceutical Co., Ltd. ("Boda") to Zhuhai Rongding Equity Investment Partnership L.P. for a total cash consideration of RMB400 million (US$65.2 million). Boda is currently the manufacturer of Yidasheng. In accordance with U.S. GAAP, assets and liabilities associated with the sale have been classified as "held for sale" and Boda's quarterly operating results are presented as discontinued operations. The preliminary unaudited condensed consolidated statements of income have been retrospectively modified to distinguish between continuing operations and discontinued operations.

"In the second quarter of 2013, our total revenue was impacted by the government's pricing policy, government restrictions on the use of antibiotics and market competition," said Mr. Hongquan Liu, Executive Director and Chief Executive Officer of Simcere Pharmaceutical Group. "Due to the changing market environment, we expect that the second half of the year will remain challenging."

Mr. Liu added, "We are encouraged by the collaboration announced in June of this year between Simcere and Bristol-Myers Squibb on the development of the subcutaneous (SC) formulation Orencia® (abatacept) for the treatment of rheumatoid arthritis. We have submitted a clinical trial application for Orenica® which has been accepted by the CFDA."

2013 Second Quarter Financial Results Revenue from continuing operations for the second quarter of 2013 was RMB483.0 million (US$78.7 million), compared to RMB498.1 million for the second quarter of 2012, representing a decrease of 3.0%. Revenue from continuing operations for the first six months of 2013 was RMB986.9 million (US$160.8 million), representing an increase of 2.9% from RMB959.1 million for the same period in 2012.

The tables below set forth the Company's top 10 products, excluding Yidasheng which is manufactured by Boda, a subsidiary to be disposed by the Company, by revenue for the three months ended June 30, 2013 and the six months ended June 30, 2013:In ThousandsThree months ended June 30, 2013Three months ended June 30, 2012RMB USD % of total
revenue RMB % of total
revenueChange ProductsTherapeutic Area Bicun

Neuroscience

124,37620,26525.8%152,62230.6%(18.5%)Endu

Oncology

88,32214,39118.3%66,77913.4%32.3%Sinofuan

Oncology

45,7867,4609.5%41,6838.4%9.8%Yintaiqing

Inflammation 45,1177,3519.3%43,9288.8%2.7%Zailin

Infectious Disease

42,7266,9628.8%61,63012.4%(30.7%)Biqi

Gastroenterology

27,1744,4285.6%26,8125.4%1.4%Jiebaishu

Oncology

18,9173,0823.9%19,5073.9%(3.0%)Anxin

Infectious Disease

12,5082,0382.6%14,7753.0%(15.3%)Faneng

Anti-Osteoporosis

12,4902,0352.6%8,7751.8%42.3%Lowvo

Oncology

9,6671,5752.0%8,3851.7%15.3%Others 55,9129,11011.6%53,16810.6%5.2%Total 482,99578,697100.0%498,064100.0%(3.0%)Six months ended June 30, 2013Six months ended June 30, 2012RMBUSD% of total
revenueRMB% of total
revenueChangeProductsTherapeutic AreaBicun

Neuroscience

250,56940,82725.4%288,01530.0%(13.0%)Endu

Oncology

168,55027,46317.1%123,12812.8%36.9%Zailin

Infectious Disease

105,29517,15610.7%121,66212.7%(13.5%)Yintaiqing

Inflammation

93,57315,2469.5%77,0758.0%21.4%Sinofuan

Oncology

78,43012,7797.9%80,9738.4%(3.1%)Biqi

Gastroenterology

51,5938,4065.2%48,7205.1%5.9%Jiebaishu

Oncology

36,0705,8773.7%34,7343.6%3.8%Anxin

Infectious Disease

29,1344,7473.0%30,2893.2%(3.8%)Faneng

Anti-Osteoporosis

25,9934,2352.6%17,6461.8%47.3%Kechuanning

Respiratory

23,3993,8132.4%24,5422.6%(4.7%)Others124,34020,25912.5%112,26911.8%10.8%Total986,946160,808100.0%959,053100.0%2.9%Gross margin from continuing operations was 83.1% for the second quarter of 2013 compared to 84.5% for the second quarter of 2012. The decrease was mainly due to a drop in sales of products with higher gross margins as a percentage of total sales. Gross margin from continuing operations was 81.5% for the first six months of 2013 compared to 83.8% for the same period in 2012.

Research and development expenses from continuing operations for the second quarter of 2013 totaled RMB45.2 million (US$7.4 million) which represented a decrease of 16.5% from RMB54.1 million for the same period in 2012. The decrease occurred as the Company completed development of its influenza vaccine and began commercial manufacturing. As a percentage of revenue from continuing operations, research and development expenses from continuing operations decreased to 9.3% for the second quarter of 2013 from 10.9% for the same period in 2012. For the first six months of 2013, research and development expenses from continuing operations totaled RMB89.3 million (US$14.5 million), compared to RMB101.3 million for the same period in 2012.

Sales, marketing and distribution expenses from continuing operations for the second quarter of 2013 were RMB280.3 million (US$45.7 million), which represented a decrease of 0.8% from RMB282.7 million for the same period in 2012. As a percentage of total revenue from continuing operations, sales, marketing and distribution expenses from continuing operations increased to 58.0% for the second quarter of 2013 from 56.7% for the same period in 2012. For the first six months of 2013, sales, marketing and distribution expenses from continuing operations were RMB536.4 million (US$87.4 million), which represented an increase of 0.4% from RMB534.2 million for the same period in 2012.

General and administrative expenses from continuing operations were RMB65.3 million (US$10.6 million) for the second quarter of 2013, which represented an increase of 27.1% from RMB51.4 million for the same period in 2012. The increase was primarily due to legal and professional fees incurred during the Company's going-private process and the share-based compensation expenses as noted in the paragraph below. As a percentage of revenue from continuing operations, general and administrative expenses increased to 13.5% for the second quarter of 2013 from 10.3% for the same period in 2012. For the first six months of 2013, general and administrative expenses from continuing operations were RMB126.6 million (US$20.6 million), which represented an increase of 12.8% from RMB112.2 million for the same period in 2012.

Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB8.5 million (US$1.4 million) for the second quarter of 2013. Share-based compensation expenses for the second quarter of 2012 were RMB2.7 million. For the first six months of 2013, share-based compensation expenses totaled RMB18.2 million (US$3.0 million), which represented an increase of 179% from RMB6.5 million for the same period in 2012. The increase was primarily due to restricted shares granted to our management in the second half of 2012.

Operating income from continuing operations was RMB10.7 million (US$1.7 million) for the second quarter of 2013, which represented a decrease of 67.5% from RMB33.0 million for the same period in 2012. For the first six months of 2013, operating income from continuing operations was RMB52.3 million (US$8.5 million), which represented a decrease of 27.3% from RMB72.0 million for the same period in 2012.

Income tax benefit from continuing operations for the second quarter of 2013 was RMB10.3 million (US$1.7 million), resulting from the reversal of the unrecognized tax benefits and related accrued cumulative interest as a result of a lapse of the statute of limitations in accordance to the PRC Tax Administration and Collection Law, compared to income tax expense of RMB0.5 million for the second quarter in 2012. For the first six months of 2013, income tax benefit from continuing operations was RMB4.8 million (US$ 0.8 million) compared to income tax expense of RMB2.7 million for the same period in 2012.

Income from discontinued operations, net of tax, was RMB14.5 million (US$2.4 million) and RMB7.6 million for the second quarter of 2013 and 2012, respectively. For the first six months of 2013, income from discontinued operations, net of tax, was RMB21.8 million (US$3.5 million), up 122.0% from RMB9.8 million for the same period in 2012.

Net income attributable to Simcere was RMB22.7 million (US$3.7 million) for the second quarter of 2013, which consists of net income attributable to Simcere from continuing operations of RMB8.2 million (US$1.3 million) and net income attributable to Simcere from discontinued operations of RMB14.5 million (US$2.4 million). Net income attributable to Simcere from continuing operations for the second quarter of 2013 decreased by 57.6% from RMB19.4 million for the same period in 2012. Net margin from continuing operations, which represents net income attributable to Simcere from continuing operations divided by revenue from continuing operations, was 1.7% for the second quarter of 2013, compared to 3.9% for the second quarter of 2012. For the first six months of 2013, net income attributable to Simcere was RMB52.7 million (US$8.6 million) which consists of net income attributable to Simcere from continuing operations of RMB30.9 million (US$5.0 million) and net income attributable to Simcere from discontinued operations of RMB21.8 million (US$3.5 million). For the first six months of 2012, net income attributable to Simcere was RMB55.6 million which consists of net income attributable to Simcere from continuing operations of RMB45.8 million and net income attributable to Simcere from discontinued operations of RMB9.8 million. Net margin from continuing operations was 3.1% for the first six months of 2013, compared to 4.8% for the same period in 2012.

Basic and diluted earnings per American Depository Share ("ADS") from continuing operations for the second quarter of 2013 were RMB0.16 (US$0.03) and RMB0.15 (US$0.02), respectively. Basic and diluted earnings per ADS from continuing operations for the first six months of 2013 were RMB0.59 (US$0.10) and RMB0.58 (US$0.09), respectively. Basic and diluted earnings per ADS from discontinued operations for the second quarter of 2013 were RMB0.28 (US$0.05) and RMB0.27 (US$0.04), respectively. Basic and diluted earnings per ADS from discontinued operations for the first six months of 2013 were RMB0.41 (US$0.07) and RMB0.41 (US$0.07), respectively. One ADS represents two ordinary shares of the Company.

As of June 30, 2013, the Company had cash and restricted cash of RMB643.4 million (US$104.8 million), compared to RMB201.6 million as of December 31, 2012. The increase was primarily due to cash consideration received related to sell of equity interest in Shanghai Celgen.

Financial InformationThe preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.

Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference CallSimcere Pharmaceutical Group will host a conference call to discuss the Company's results for the second quarter of 2013 on August 13th 2013, at 8:00 a.m. Eastern Time (Tuesday, August 13th at 8:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for the second quarter of 2013 and to answer questions.

To access the conference call, please dial:International toll: +65.6723.9381United States toll-free: +1.866.519.4004United States toll: +1.845.675.0437China Domestic toll: 800.819.0121 China Domestic mobile toll: 400.620.8038 Hong Kong toll: +852.2475.0994Please ask to be connected to Q2 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 23263347.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the Company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free: +1. 855.452.5696United States toll: +1. 646.254.3697The passcode for replay participants is 23263347. The telephone replay also will be archived on the "Investor Relations" section of the Company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy, such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing: In the United States:Jie Liu D'Elia

Cindy ZhengVice President

Brunswick GroupSimcere Pharmaceutical Group

Tel: 1-212-333-3810Tel: 86-25-8556-6666*8857 In Beijing: Yue Yu Brunswick Group Tel: 86-10-5960-8600 SIMCERE PHARMACEUTICAL GROUPPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME(AMOUNTS EXPRESSED IN THOUSANDS, EXCEPT SHARE AND ADS DATA) Three months ended June 30,Six months ended June 30,201220132013201220132013RMBRMBUSDRMBRMBUSDProduct revenue

498,064

482,995

78,697959,053

986,946

160,808Total revenue498,064482,99578,697959,053986,946160,808Cost of materials and production

(76,976)

(81,540)

(13,286)(155,007)

(182,390)

(29,717)Gross profit421,088401,45565,411804,046804,556131,091Operating expenses and other operating
income:Research and development

(54,060)

(45,150)

(7,356)(101,283)

(89,298)

(14,550)Sales, marketing and distribution

(282,650)

(280,277)

(45,667)(534,216)

(536,369)

(87,394)General and administrative

(51,378)

(65,314)

(10,642)(112,229)

(126,554)

(20,620)Other operating income

-

-

-15,650

-

-Income from operations33,00010,7141,74671,96852,3358,527Interest income

1,125

991

1611,958

1,845

301Interest expense

(18,394)

(10,961)

(1,786)(36,891)

(23,707)

(3,863)Foreign currency exchange losses

(546)

(350)

(57)(603)

(376)

(61)Other  income

108

3,571

5824,189

4,711

767Equity in losses of equity method affiliated
company

(2,383)

(11,273)

(1,837)(4,926)

(23,126)

(3,768)Earnings (losses)  from continuing
operations before income taxes 12,910(7,308)(1,191)35,69511,6821,903Income tax (expenses) benefits

(506)

10,310

1,680(2,738)

4,819

786Net Income from continuing operations12,4043,00248932,95716,5012,689Earnings from discontinued operations
before income taxes

7,337

17,264

2,8139,962

25,535

4,160Income tax benefits (expenses)

250

(2,748)

(448)(155)

(3,763)

(613)Income from discontinued operations,
net of tax7,58714,5162,3659,80721,7723,547Net Income19,99117,5182,85442,76438,2736,236Net loss attributable to the non-controlling interests

6,983

5,226

85212,834

14,414

2,349Net income attributable to
Simcere Pharmaceutical Group
shareholder 

26,974 

22,744 

3,706 

55,598 

52,687 

8,585Net income attributable to Simcere
Pharmaceutical Group shareholder from
continuing operations19,3878,2291,34145,79230,9175,038Net income attributable to Simcere
Pharmaceutical Group shareholder from
discontinued operations

7,587

14,515

2,3659,806

21,770

3,547Earnings per share attributable to
Simcere from continuing
operations:Basic

0.18

0.08

0.010.42

0.29

0.05Diluted

0.18

0.08

0.010.42

0.29

0.05Earnings  per share attributable to
Simcere from discontinued
operations:Basic

0.07

0.14

0.020.09

0.21

0.03Diluted

0.07

0.14

0.020.09

0.21

0.03Earnings per ADS attributable to
Simcere from continuing
operations:Basic

0.36

0.16

0.030.85

0.59

0.10Diluted

0.36

0.15

0.020.85

0.58

0.09Earnings  per ADS attributable to
Simcere from discontinued
operations:Basic

0.14

0.28

0.050.18

0.41

0.07Diluted

0.14

0.27

0.040.18

0.41

0.07Weighted average number of ordinary
shares:

 Basic

107,834,280

105,308,644

105,308,644108,136,224

105,233,637

105,233,637Diluted

107,961,891

107,103,181

107,103,181108,329,408

106,691,583

106,691,583 SIMCERE PHARMACEUTICAL GROUPPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS EXPRESSED IN THOUSANDS) December 31,June 30,June 30,201220132013RMBRMBUSDAssetsCurrent assetsCash and pledged bank deposits

201,556

643,388

104,831Assets held for sale

90,550

267,185

43,534Bills receivable

679,630

607,575

98,996Accounts receivable, net

413,481

479,308

78,096Inventories120,932117,51119,147Other current assets

237,248

215,508

35,113Total current assets1,743,3972,330,475379,717Property, plant and equipment, net

853,546

785,904

128,052Land use rights

128,220

118,285

19,273Goodwill and intangible assets, net

519,334

427,315

69,625Investment in equity method investments

56,785

34,408

5,606Other non-current assets

71,381

111,990

18,247Total assets3,372,663

3,808,377

620,520LiabilitiesCurrent liabilitiesShort-term borrowings

675,779

742,290

120,945Accounts payable

47,136

50,567

8,239Bills payable15,00020,0003,259Other payables and accrued liabilities

471,603

767,919

125,122Liabilities directly associated with assets held for sale

-

35,843

5,840Total current liabilities1,209,5181,616,619263,405Long-term borrowings

2,000

2,000

326Deferred tax liabilities 56,12039,9586,510Other liabilities

32,657

21,195

3,453Total liabilities1,300,2951,679,772273,694Shareholders' equitySimcere shareholders' equity Ordinary shares at par

8,258

8,266

1,347Additional paid-in capital

853,551

871,837

142,053Accumulated other comprehensive loss

(104,147)

(104,476)

(17,022)Retained earnings1,254,4641,307,151212,981Total equity attributable to Simcere2,012,1262,082,778339,359Non-controlling interest

60,242

45,827

7,467Total shareholders' equity2,072,3682,128,605346,826Commitments and contingenciesTotal liabilities and shareholders' equity3,372,663

3,808,377

620,520Note: The conversions of Renminbi (RMB) into United States dollars (USD) as at the reporting dates are based on the noon buying rate of USD1.00 = RMB6.1374 on June 28, 2013 as set forth in the H. 10 statistical release of the Federal Reserve Board. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on the reporting dates.

• AIDS/HIV
• Bioinformatics
• Biotechnology
• Biochemistry
• Cancer
• Cell Biology
• Developmental Biology
• Ecology
• Environment
• Evolution
• Food Technology
• Gene
• Genetics
• Genomics
• Health/Medicine
• Immunology
• Microarray
• Microbiology
• Molecular
• Marine Biology
• Nanobiotechnology
• Neurobiology
• Plant Sciences
• Stem Cell
• Systems Biology
• Virus
• Women Health

• Abortion
• Aches
• ADHD
• Addiction
• Alcohol
• Allergy
• Alternative Medicine
• Alzheimer's Dementia
• Anxiety/Stress
• Arthritis
• Autism
• Bacteria
• Blood
• Bird Flu/Avian Flu
• Bones
• Breast Cancer
• Cancer
• Cardiovascular
• Cervical Cancer
• Chikungunya
• Cholesterol
• Clinical Trials
• Colorectal Cancer
• Conferences
• Crohn's
• Cystic Fibrosis
• Dengue
• Dentistry
• Depression
• Diabetes
• Drug
• Eating Disorders
• Education
• Epilepsy
• Erectile Dysfunction
• Eye Health/Blindness
• Fertility
• Flu/Cold
• GastroIntestinal
• Genetics
• Gout
• Headache/Migraine
• Hearing/Deafness
• HIV/AIDS
• Huntington's Disease
• Hypertension
• Immune System/Vaccines
• Insurance
• Infectious Diseases
• Irritable-Bowel Syndrome
• Internet
• Leukemia
• Lifestyle
• Liver Disease/Hepatitis
• Lung Cancer
• Lupus
• Mad Cow Disease
• Medical Devices
• Medical Students/Training
• Medicare/Medicaid
• Medico
• Men's health
• Mental Health
• MRI/Ultrasound
• MRSA/Drug Resistance
• Multiple Sclerosis
• Muscular Dystrophy
• Neurology
• Nursing
• Nutrition/Diet
• Obesity/Weight Loss
• Pain/Anesthetics
• Parkinson's Disease
• Pediatrics/Children's Health
• Pharma/Biotech Industry
• Pharmacy/Pharmacists
• Pregnancy
• Premature
• Prostate
• Psychology/Psychiatry
• Rehabilitation
• Respiratory/Asthma
• SARS
• Schizophrenia
• Seniors/Aging
• Sexual Health
• Sleep/Sleep Disorders
• Smoking
• Statins
• Stem Cell Research
• Stroke
• Surgery
• Transplants/Organ Donations
• Viruses
• Water - Air Quality
• Women's Health